DGAP-News: Defense Therapeutics Inc.

/ Key word (s): Patent

08/31/2021 / 08:30

The issuer is solely responsible for the content of this announcement.

Vancouver, BC, Canada, August 31, 2021 – Defense Therapeutics Inc. (“Defense” or the “Company”), a biotechnology company that uses its AccumTM technology works on ADC therapeutics for the targeted treatment of cancer and cancer vaccines as well as vaccines against infectious diseases, is pleased to announce the expansion of its patent portfolio with the filing of its US preliminary patent application based on AccumTM technology called “Steroid Acid-Based Hydrogel”.

Hydrogels are cross-linked polymer networks that can swell and retain a considerable amount of water in their structure. Hydrogels are widely used in various industries and have a wide variety of applications such as pharmaceuticals and therapeutics (drug delivery systems), biomedicine, food additives, cosmetics (hygiene products), the environment, energy, agriculture and mining for drainage.

The novel AccumTM hydrogel from Defense formed spontaneously within seconds immediately after resuspension at room temperature. Hydrogel formation was assessed after dissolving the various AccumTM peptide or steroid acid peptide variants of AccumTM in various aqueous solvents. It has been found that the kinetics of hydrogel formation depend on the steroid acid-peptide conjugate, the concentration of the steroid acid-peptide conjugate and the aqueous solvent used.
“The hydrogel sector is growing rapidly and the versatility of Defense’s AccumTM technology provides Defense with yet another business opportunity that the Defense team is looking to take to a commercialization level. Defense will participate in this emerging market with our laboratory studies that clearly show the positive result have shown that various steroid acid hnRNPA1 (a variant of AccumTM) will spontaneously and rapidly form a new hydrogel when dissolved in different aqueous solvents at different temperatures and concentrations. Defense’s novel AccumTM hydrogel will be able to do so due to its versatility to cater to each client’s personal specific needs, “said Sébastien Plouffe, Chief Executive Officer of Defense.

According to the new Expert Market Research report entitled” Global Hydrogel Market Size, Share, Price, Trends, Growth, Analysis, Report and Forecast 2021-2026 “is the global Hydrogel Market a shower field with sales of $ 23.6 billion in 2020 and an expected CAGR of 7.0% over the next five years to $ 35.5 billion in 2026. The diverse uses of hydrogel such as medical fields , Industrial and Consumer Products will drive the hydrogel market.

Key players in the biotech / pharmaceutical industry are Alcon (Novartis AG), Johnson & Johnson Services Inc., and 3M Company.

About Defense:
Defense Therapeutics is a publicly traded biotechnology company working to develop the next generation of vaccines and ADC products using its proprietary platform. At the heart of the Defense Therapeutics platform is ACCUMTM technology, which enables the precise delivery of vaccine antigens or ADCs in their intact form to target cells. As a result, increased effectiveness and potency against catastrophic diseases such as cancer and infectious diseases can be achieved.

For more information:
Sebastien Plouffe, President, CEO and Director
P: (514) 947-2272 [email protected] Cautionary Statement Regarding “Forward-Looking” Information
This press release contains certain statements that may be considered “forward-looking statements”. All statements in this press release, other than historical facts, dealing with events or developments that the company expects, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, characterized by the words “expected”, “plan”, “anticipated”, “believes”, “intends”, “estimates”, “projected” . , “potentially” and similar expressions; or that events or conditions “will”, “would”, “may”, “could” or “should”. Although the company believes that the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include regulatory measures, market prices and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that such statements are no guarantees of future performance and that actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the company’s management at the time these statements are made. Except as required by applicable securities laws, the company assumes no obligation to update these forward-looking statements if management’s views, estimates, or opinions or other factors change.
Neither the CSE nor its Market Authority, as this term is defined in the guidelines of the CSE, accepts responsibility for the adequacy or accuracy of this press release.

08/31/2021 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. The issuer is responsible for the content of this announcement. DGAP’s sales services include approval notifications, financial / company news and press releases. Archive on www.dgap.de

PharmiWeb.com is Europe’s leading industry sponsored portal for the pharmaceutical sector, providing the latest job vacancies, news, features and event announcements. The information provided on PharmiWeb.com is intended to establish the relationship between a patient / website visitor and his / her doctor.

This website is protected by reCAPTCHA and the Google Privacy Policy and Terms of Use apply.

follow us

Copyright © 2021 PHARMIWEB.COM LIMITED, rights reserved to their respective owners.

Disclaimer: You are now leaving the PharmiWeb.com website and switching to a website that is not operated by us. We are not responsible for the content or availability of linked pages.

PharmiWeb.com provides links to other third-party websites that may be of interest to our website visitors. The links provided on our website are provided for your convenience only and may help you find other useful information on the Internet. If you click on these links you will leave the PharmiWeb.com website and be redirected to another website. These websites are not under the control of PharmiWeb.com.

PharmiWeb.com is not responsible for the content of linked third party websites. We are not agents for these third parties, nor do we support or guarantee their products. We do not give any representations or warranties with regard to the correctness of the information contained on the linked pages. We recommend that you always check the information received from linked websites before responding to this information.

Please also note that the security and privacy policies on these websites may differ from the policies of PharmiWeb.com. Therefore, read the privacy and security policies of third party providers carefully.

If you have any questions or concerns about the products and services offered on linked third party websites, please contact the third party directly.

Related Titles :
DEFENSE THERAPY FILES ACID-BASED HYDROGELS PROVISIONAL USA / a>

Ref: https://www.pharmiweb.com